stockportfolio.pro
Stocks / INSM vs MRNA
INSM vs MRNA
Insmed Incorporated and Moderna, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Insmed Incorporated (INSM) | Moderna, Inc. (MRNA) | |
|---|---|---|
| Market cap | $20.9B | $20.7B |
| Revenue (latest FY) | $606.42M | $1.94B |
| Net income (latest FY) | $-1.28B | $-2.82B |
| Revenue growth (5y CAGR) | 29.8% | 19.3% |
| Net margin | -210.5% | -145.2% |
| Return on equity | -172.8% | -32.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open INSM — free Open MRNA — freeFrequently asked questions
Which is bigger, INSM or MRNA?
Insmed Incorporated is larger by market capitalization — $20.9B versus $20.7B.
Which grows faster, INSM or MRNA?
Over the last five fiscal years, Insmed Incorporated grew revenue faster — 29.8%/yr versus 19.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.